E
DNTH icon

Ergoteles’s Dianthus Therapeutics DNTH Stock Holding History

Ergoteles’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,363
Closed -$8.61K – 1376
2022
Q4 		$8.61K Sell
1,363
-5,832
-81% -$103K ﹤0.01% 1373
2022
Q3 		$162K Sell
7,195
-1,010
-12% -$27.7K 0.01% 1253
2022
Q2 		$158K Buy
+8,205
New +$203K ﹤0.01% 1402

Other funds holding DNTH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return
TG
TCW Group Los Angeles, California $14.9B AUM 46.29% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Ergoteles's DNTH Position: Q1 2023 in Review

Ergoteles sold out of Dianthus Therapeutics (DNTH) in Q1 2023, closing a stake of 1,363 shares — an estimated $8.61K sold.

Ergoteles first reported a position in DNTH in Q2 2022 and held it in 3 quarters. The position peaked at $162K in Q3 2022. 52 funds tracked by Wall St. Rank hold DNTH as of Q1 2023.

  • Ergoteles reported no remaining Dianthus Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 1,363 Dianthus Therapeutics shares in Q1 2023, an estimated $8.61K.
  • Ergoteles first reported a position in Dianthus Therapeutics in Q2 2022 and held it in 3 quarters.
  • Ergoteles's Dianthus Therapeutics position peaked at $162K in Q3 2022.
  • 52 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.